Patents by Inventor Gumersinda Bombino Lopez

Gumersinda Bombino Lopez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions including the anti-idiotypic monoclonal antibodies
    Patent number: 6491914
    Abstract: An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an immunomodulator for cancer treatment. Specifically, the anti-Id monoclonal antibody of the present invention is capable of inducing a predominant anti-idiotypic response in xenogeneic models. The anti-idiotypic monoclonal antibody also exerts a protective effect against malignant tumors in animals.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: December 10, 2002
    Assignee: Centro de Inmunologia Molecular
    Inventors: Ana Maria Vázguez López, Rolando Pérez Rodriguez, Eladio Iglesis Guerra, Alexis Pérez, Gumersinda Bombino Lopez, Irene Beausoleil Delgado
  • Monoclonal anti-idiotypic antibodies (AB2) and their uses
    Patent number: 6433148
    Abstract: The present invention describes the selection and use of antidiotypic monoclonal antibodies. (AB2) IgG type with the main characteristic of being highly connected to the idiotipic network and recognition of B and T human lymphocytes, which are major participants in the immune response. According to the previous statement the objective of this invention is to provide antidiotypic monoclonal antibodies IgG type connected to the immune network, able to interact with T and B lymphocytes and able to exert an immunoregulatory effect, irmunostimulation or immunosupression that can be used for immunotherapy of autoimune diseases, infectious diseases and cancer.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: August 13, 2002
    Assignee: Centro de Immunologia Molecular (CIM)
    Inventors: Amparo Emilia Macias Abrahan, Rolando Perez Rodriguez, Teresita Rodriguez Obaya, Mercedes Ramos Zamora, Gumersinda Bombino Lopez, Orlando Pena Marichal
  • Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
    Patent number: 6063379
    Abstract: An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an immunomodulator for cancer treatment. Specifically, the anti-idiotype monoclonal antibody of the present invention is capable of inducing a predominant anti-idiotypic response in xenogeneic models. The anti-idiotypic monoclonal antibody also exerts a protective effect against malignant tumors in animals.
    Type: Grant
    Filed: January 29, 1998
    Date of Patent: May 16, 2000
    Assignee: Centro de Inmunologia Molecular
    Inventors: Ana Maria Vazguez Lopez, Rolando Perez Rodriguez, Eladio Iglesis Guerra, Alexis Perez, Gumersinda Bombino Lopez, Irene Beausoleil Delgado